Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.65 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.61 |
| ▸ | CASP3 | P42574 | 2/20 | 0.59 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.55 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.53 |
| ▸ | RELA | Q04206 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19555861 | 0.82 | NOTUM (0.61) | NR1H4NOTUMCASP3SMN1; SMN2RAB9A | |
| SCHEMBL1473020 | 0.79 | NR1H4 (1.00) | NR1H4NOTUMCASP3GPR55SMN1; SMN2 | |
| SCHEMBL6367494 | 0.78 | NPC1 (0.53) | NR1H4NOTUMCASP3SMN1; SMN2RAB9A | |
| SCHEMBL17100937 | 0.78 | NR1H4 (0.68) | NR1H4CASP3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL28651531 | 0.78 | NR1H4 (0.78) | NR1H4CASP3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL28637707 | 0.78 | NR1H4 (0.78) | NR1H4CASP3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7958860 | 0.76 | SMN1; SMN2 (0.65) | NR1H4NOTUMCASP3GPR55SMN1; SMN2 | |
| SCHEMBL6384839 | 0.76 | NR1H4 (0.63) | NR1H4NOTUMCASP3GPR55SMN1; SMN2 | |
| SCHEMBL12895776 | 0.76 | NR1H4 (0.83) | NR1H4NOTUMCASP3GPR55SMN1; SMN2 | |
| SCHEMBL255502 | 0.76 | L3MBTL1 (0.74) | NR1H4NOTUMCASP3GPR55SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | BREYE THERAPEUTICS APS (DK) | 2026-02-10 | — | — | US | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4262975-B1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2025-03-05 | — | — | EP | disclosed |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-05 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| CN-111712492-B | Cyclotriazoles as LPA antagonists | 百时美施贵宝公司 | 2024-05-31 | — | — | CN | disclosed |
| US-11970486-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-30 | — | — | US | disclosed |
| EP-2686312-A1 | N- CYCLOPROPYL - N- PIPERIDINYLBENZAMIDES AS GPR119 MODULATORS | Boehringer Ingelheim International GmbH (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-20130065906-A1 | New compounds, pharmaceutical compositions and uses thereof | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2012123449-A1 | N- CYCLOPROPYL - N- PIPERIDINYLBENZAMIDES AS GPR119 MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-20 | — | — | WO | disclosed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-0446010-B1 | Imidazole derivatives and antiepileptics comprising said imidazole derivatives as effective ingredients | MITSUI TOATSU CHEMICALS (JP) | 1995-03-08 | — | — | EP | disclosed |
| US-5112841-A | Anticonvulsants | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0446010-A1 | Imidazole derivatives and antiepileptics comprising said imidazole derivatives as effective ingredients | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-09-11 | — | — | EP | disclosed |
| US-4207234-A | 4-Unsubstituted azetidinone derivatives and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065906-A1 | New compounds, pharmaceutical compositions and uses thereof | GPR119, GPR55, GPR65 | NR1H4 169/4885NOTUM 4211/4885CASP3 4725/4885 |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | NR1H4 95/4885NOTUM 2646/4885CASP3 2200/4885 |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | NR1H4 1341/4885NOTUM 211/4885CASP3 693/4885 |
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | NR1H4 332/4885NOTUM 1437/4885CASP3 1982/4885 |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | NR1H4 1341/4885NOTUM 211/4885CASP3 693/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | NR1H4 1341/4885NOTUM 211/4885CASP3 693/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | NR1H4 95/4885NOTUM 2646/4885CASP3 2200/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | NR1H4 1479/4885NOTUM 2435/4885CASP3 4375/4885 |
| US-12545682-B2 | Heterocyclic derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | NR1H4 755/4885NOTUM 4814/4885CASP3 1107/4885 |
| US-11970486-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | NR1H4 1341/4885NOTUM 211/4885CASP3 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.